Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, no par value
-
Shares outstanding
-
7.1M
-
Number of holders
-
62
-
Total 13F shares, excl. options
-
6.03M
-
Shares change
-
+791K
-
Total reported value, excl. options
-
$366M
-
Value change
-
+$48.4M
-
Number of buys
-
36
-
Number of sells
-
-14
-
Price
-
$60.66
Significant Holders of BRIGHT MINDS BIOSCIENCES INC. - Common Stock, no par value (DRUG) as of Q3 2025
63 filings reported holding DRUG - BRIGHT MINDS BIOSCIENCES INC. - Common Stock, no par value as of Q3 2025.
BRIGHT MINDS BIOSCIENCES INC. - Common Stock, no par value (DRUG) has 62 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 6.03M shares
of 7.1M outstanding shares and own 85.04% of the company stock.
Largest 10 shareholders include JANUS HENDERSON GROUP PLC (1.15M shares), Cormorant Asset Management, LP (1.06M shares), Vivo Capital, LLC (502K shares), Commodore Capital LP (500K shares), PERCEPTIVE ADVISORS LLC (449K shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (396K shares), BRAIDWELL LP (304K shares), BlackRock, Inc. (234K shares), MORGAN STANLEY (193K shares), and Sio Capital Management, LLC (191K shares).
This table shows the top 62 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.